OncoMatch/Clinical Trials/NCT06580314
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Is NCT06580314 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Bevacizumab and Olaparib for fallopian tube endometrioid adenocarcinoma.
Treatment: Bevacizumab · Olaparib — This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 deleterious alteration
Documented variant (tumor or germline) in BRCA1 or BRCA2 that is predicted to be pathogenic or suspected pathogenic (deleterious alteration)
Required: BRCA2 deleterious alteration
Documented variant (tumor or germline) in BRCA1 or BRCA2 that is predicted to be pathogenic or suspected pathogenic (deleterious alteration)
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (other)
FIGO stage III or IV ovarian cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — first line
Patients must have completed first line platinum-based therapy prior to registration: Platinum based chemotherapy course must have consisted of a minimum of 4 treatment cycles and a maximum of 9, although it is strongly recommended that patients receive at least 6 cycles unless medically contraindicated
Cannot have received: PARP inhibitor (olaparib, niraparib, rucaparib)
No previous treatment with a PARP inhibitor, including olaparib, niraparib, and rucaparib
Cannot have received: investigational agent
Patients must not have received an investigational agent during their first line course of chemotherapy
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 9 g/dl
Kidney function
Creatinine clearance (CrCL) of > 30 mL/min by the Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); AST and ALT ≤ 3 x institutional ULN
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
ANC ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 9 g/dl; Creatinine clearance (CrCL) of > 30 mL/min by the Cockcroft-Gault formula; Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled); AST and ALT ≤ 3 x institutional ULN; cardiac risk assessment: NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06580314 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP inhibitor, investigational agent disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 deleterious alteration is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 deleterious alteration is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages